Key facts
- This page summarizes Stephen Quake's Form 4 filing for AbCellera Biologics Inc. (ABCL).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Jun 2026, 13:03.
Stephen Quake - 11 Jun 2026 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)
- Reporting relationship
- Director
- Issuer ticker
- ABCL
- Reported as of
- 11 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Jun 2026, 13:03:15 UTC
- Prior SEC filing
- 19 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- Tryn Stimart, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stephen Quake filed Form 4 for AbCellera Biologics Inc. (ABCL) on 12 Jun 2026.
Change
- Previous filing in this sequence was filed on 19 Dec 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001685889
Primary reporting owner
Quake Stephen
- Relationship
- Director
- Address
- ABCELLERA BIOLOGICS INC, 150 W 4TH AVENUE, VANCOUVER, BRITISH COLUMBIA, CANADA
- Signature
- Tryn Stimart, attorney-in-fact
- Signature date
- 12 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABCL
transaction
Derivative
Share option (right to buy)
Award
- Transaction value
- Shares
- +111,701
- Change %
- +57%
- Price
- $0.000000*
- Shares after
- 306,633
- Date
- 11 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 111,701
- Exercise price
- $5.27
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date.